SCHEMBL85762

SCHEMBL85762

O=C(OCl)C(Br)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
TSHR P16473 3/20 0.40
ALOX15 P16050 2/20 0.40
CYP2C9 P11712 3/20 0.39
MEN1 O00255 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
KMT2A Q03164 2/20 0.39
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
GABBR2 O75899 3/20 0.37
GABBR1 Q9UBS5 3/20 0.37
LMNA P02545 2/20 0.37
FFAR2 O15552 1/20 0.37
CYP3A4 P08684 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473478 0.82 L3MBTL1 (0.49) BRD4HDAC4HDAC7HDAC5KMT2A
SCHEMBL4008344 0.82 CES2 (0.59) HDAC4HDAC7HDAC5CYP2D6KMT2A
SCHEMBL14422345 0.79 MEN1 (0.47) BRD4HDAC4HDAC7HDAC5TSHR
SCHEMBL5321055 0.79 CA12 (0.47) BRD4TSHRLMNACYP3A4CYP1A2
SCHEMBL75753 0.77 CES2 (0.52) BRD4HDAC4HDAC7HDAC5TSHR
SCHEMBL9298853 0.77 CES2 (0.52) BRD4HDAC4HDAC7HDAC5TSHR
SCHEMBL9298515 0.77 BRD4 (0.45) BRD4HDAC4HDAC7HDAC5TSHR
SCHEMBL75858 0.77 BRD4 (0.45) BRD4HDAC4HDAC7HDAC5TSHR
SCHEMBL5742269 0.77 CES2 (0.46) BRD4HDAC4HDAC7HDAC5TSHR
SCHEMBL5356165 0.75 MEN1 (0.46) BRD4HDAC4HDAC7HDAC5TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof OPRM1, OPRD1, ADRA1D BRD4 3460/4885HDAC4 3292/4885HDAC7 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.